Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer.

08:00 EDT 5th April 2019 | BioPortfolio

Summary of "Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer."

Previous studies have shown that continued smoking among patients with cancer can increase overall and cancer-specific mortality, risk for second primary cancer, and risk for toxic effects of cancer treatment. To our knowledge, there have been no efforts to estimate additional costs for cancer treatment attributed to smoking.


Journal Details

This article was published in the following journal.

Name: JAMA network open
ISSN: 2574-3805
Pages: e191703


DeepDyve research library

PubMed Articles [35196 Associated PubMed Articles listed on BioPortfolio]

Household costs of breast cancer morbidity: An empirical assessment from Pakistan.

Health care costs attributable to breast cancer are substantial. In countries with high poverty, lack of public health infrastructure and low availability of health insurance, the economic burden of d...

Total and out-of-pocket costs of different primary management strategies in ovarian cancer.

Communicating healthcare costs to patients is an important component of delivering high-quality value-based care, yet cost data is lacking. This is especially relevant for ovarian cancer, where no cli...

TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.

Colorectal cancer is one of the most common cancers and causes of cancer-related death. Up to approximately 70% of patients with metastatic colorectal cancer (mCRC) have metastases to the liver at ini...

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.

Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment ...

Counting the costs of complications in colorectal surgery.

New Zealand has a high incidence of colorectal cancer. Most patients are treated with resectional surgery. There is a significant rate of complication associated with treatment. Costs of surgical trea...

Clinical Trials [19799 Associated Clinical Trials listed on BioPortfolio]

Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients

To better understand the public health prognostic impact of noncardiac chronic illnesses, we explored the attributable risk of noncardiac comorbidities on outcomes between heart failure pa...

Cost Assessment of Two Continuous Veno-venous Haemodiafiltration (CVVHDF) Methods in an Intensive Care Unit

Continuous veno-venous hemodiafiltration is widely used in the treatment of patients with acute renal failure. Two techniques for CVVHDF are coexisting in this hospital: classical CVVHDF a...

Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

Primary Aims: - To determine whether methadone used as first line strong opioid is superior to morphine as evidenced by reduced pain over a 12-week treatment period in patients wi...

Intravenous BI 6727 in 2nd Line Treatment of Urothelial Cancer

The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first li...

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

This is a multi-center retrospective study, designing to access the best treatment strategy in non-small cell lung cancer (NSCLC) patients harboring EGFR mutant type after first/second lin...

Medical and Biotech [MESH] Definitions

The evaluation of incidents involving the loss of function of a device. These evaluations are used for a variety of purposes such as to determine the failure rates, the causes of failures, costs of failures, and the reliability and maintainability of devices.

An adverse effect occurring with a medical treatment that is not attributable to the actions of the treatment.

Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs.

The expenses incurred by a hospital in providing care. The hospital costs attributed to a particular patient care episode include the direct costs plus an appropriate proportion of the overhead for administration, personnel, building maintenance, equipment, etc. Hospital costs are one of the factors which determine HOSPITAL CHARGES (the price the hospital sets for its services).

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

Quick Search


DeepDyve research library

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Searches Linking to this Article